Bisphosphonate-associated osteonecrosis of the jaw

Neil Basu, David M Reid

Research output: Contribution to journalLiterature review

7 Citations (Scopus)

Abstract

The term 'osteonecrosis of the jaw' is typically used to describe the exposure of bone within the oral cavity. These lesions are often painful and can result in pathological fracture and disfigurement in severe cases. Infection and dental extractions commonly precede presentation, although lesions can occur spontaneously. There are no clear effective management strategies; surgery often makes the situation worse. The aetiology is far from clear. Historically, it was mainly associated with exposure to 'white phosphorus' contained in safety matches. More recently, it has presented as a complication of head and neck radio-therapy. The vast majority of contemporary reports refer to high-dose intravenous bisphosphonates used in the oncological setting. However, oral bisphosphonates, for the common indication of postmenopausal osteoporosis, have also been implicated, although the number of cases is minuscule considering the number of worldwide prescriptions. Osteonecrosis of the jaw poses a significant problem in oncology, but whether this worry is transferable to metabolic bone disease only time will tell. Certainly, further research into its pathophysiology and management is merited. With regard to management of postmenopausal osteoporosis, practice should not necessarily be altered at this early stage; however, pre-treatment worries regarding dental health should perhaps instigate a precautionary dental review.
Original languageEnglish
Pages (from-to)56-59
Number of pages4
JournalMenopause International
Volume13
Issue number2
DOIs
Publication statusPublished - 1 Jun 2007

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Postmenopausal Osteoporosis
Osteonecrosis
Diphosphonates
Jaw
Tooth
Tooth Extraction
Spontaneous Fractures
Metabolic Bone Diseases
Radio
Phosphorus
Prescriptions
Mouth
Neck
Head
Safety
Bone and Bones
Health
Infection
Research

Keywords

  • bone density conservation agents
  • diphosphonates
  • female
  • Great Britain
  • humans
  • jaw diseases
  • osteonecrosis
  • osteoporosis, postmenopausal
  • women's health

Cite this

Bisphosphonate-associated osteonecrosis of the jaw. / Basu, Neil; Reid, David M.

In: Menopause International, Vol. 13, No. 2, 01.06.2007, p. 56-59.

Research output: Contribution to journalLiterature review

Basu, Neil ; Reid, David M. / Bisphosphonate-associated osteonecrosis of the jaw. In: Menopause International. 2007 ; Vol. 13, No. 2. pp. 56-59.
@article{71eda902579f487a8d472b35daae7562,
title = "Bisphosphonate-associated osteonecrosis of the jaw",
abstract = "The term 'osteonecrosis of the jaw' is typically used to describe the exposure of bone within the oral cavity. These lesions are often painful and can result in pathological fracture and disfigurement in severe cases. Infection and dental extractions commonly precede presentation, although lesions can occur spontaneously. There are no clear effective management strategies; surgery often makes the situation worse. The aetiology is far from clear. Historically, it was mainly associated with exposure to 'white phosphorus' contained in safety matches. More recently, it has presented as a complication of head and neck radio-therapy. The vast majority of contemporary reports refer to high-dose intravenous bisphosphonates used in the oncological setting. However, oral bisphosphonates, for the common indication of postmenopausal osteoporosis, have also been implicated, although the number of cases is minuscule considering the number of worldwide prescriptions. Osteonecrosis of the jaw poses a significant problem in oncology, but whether this worry is transferable to metabolic bone disease only time will tell. Certainly, further research into its pathophysiology and management is merited. With regard to management of postmenopausal osteoporosis, practice should not necessarily be altered at this early stage; however, pre-treatment worries regarding dental health should perhaps instigate a precautionary dental review.",
keywords = "bone density conservation agents, diphosphonates, female, Great Britain, humans, jaw diseases, osteonecrosis, osteoporosis, postmenopausal, women's health",
author = "Neil Basu and Reid, {David M}",
year = "2007",
month = "6",
day = "1",
doi = "10.1258/175404507780796361",
language = "English",
volume = "13",
pages = "56--59",
journal = "Menopause International",
issn = "1754-0453",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Bisphosphonate-associated osteonecrosis of the jaw

AU - Basu, Neil

AU - Reid, David M

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The term 'osteonecrosis of the jaw' is typically used to describe the exposure of bone within the oral cavity. These lesions are often painful and can result in pathological fracture and disfigurement in severe cases. Infection and dental extractions commonly precede presentation, although lesions can occur spontaneously. There are no clear effective management strategies; surgery often makes the situation worse. The aetiology is far from clear. Historically, it was mainly associated with exposure to 'white phosphorus' contained in safety matches. More recently, it has presented as a complication of head and neck radio-therapy. The vast majority of contemporary reports refer to high-dose intravenous bisphosphonates used in the oncological setting. However, oral bisphosphonates, for the common indication of postmenopausal osteoporosis, have also been implicated, although the number of cases is minuscule considering the number of worldwide prescriptions. Osteonecrosis of the jaw poses a significant problem in oncology, but whether this worry is transferable to metabolic bone disease only time will tell. Certainly, further research into its pathophysiology and management is merited. With regard to management of postmenopausal osteoporosis, practice should not necessarily be altered at this early stage; however, pre-treatment worries regarding dental health should perhaps instigate a precautionary dental review.

AB - The term 'osteonecrosis of the jaw' is typically used to describe the exposure of bone within the oral cavity. These lesions are often painful and can result in pathological fracture and disfigurement in severe cases. Infection and dental extractions commonly precede presentation, although lesions can occur spontaneously. There are no clear effective management strategies; surgery often makes the situation worse. The aetiology is far from clear. Historically, it was mainly associated with exposure to 'white phosphorus' contained in safety matches. More recently, it has presented as a complication of head and neck radio-therapy. The vast majority of contemporary reports refer to high-dose intravenous bisphosphonates used in the oncological setting. However, oral bisphosphonates, for the common indication of postmenopausal osteoporosis, have also been implicated, although the number of cases is minuscule considering the number of worldwide prescriptions. Osteonecrosis of the jaw poses a significant problem in oncology, but whether this worry is transferable to metabolic bone disease only time will tell. Certainly, further research into its pathophysiology and management is merited. With regard to management of postmenopausal osteoporosis, practice should not necessarily be altered at this early stage; however, pre-treatment worries regarding dental health should perhaps instigate a precautionary dental review.

KW - bone density conservation agents

KW - diphosphonates

KW - female

KW - Great Britain

KW - humans

KW - jaw diseases

KW - osteonecrosis

KW - osteoporosis, postmenopausal

KW - women's health

U2 - 10.1258/175404507780796361

DO - 10.1258/175404507780796361

M3 - Literature review

VL - 13

SP - 56

EP - 59

JO - Menopause International

JF - Menopause International

SN - 1754-0453

IS - 2

ER -